dr. daver discusses single-agent immunotherapy in aml
Published 6 years ago • 104 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:08
dr. daver on immune checkpoint pathways in aml
-
1:46
dr. wakelee on single-agent immunotherapy in nsclc
-
1:09
dr. daver on the rationale of azacitidine and nivolumab in acute myeloid leukemia
-
2:15
dr. daver on the utility of maintenance therapy in aml
-
1:19
dr. daver on the advancing treatment landscape in aml
-
2:18
dr. daver on benefits of cc-486 in patients with aml
-
7:54
immunotherapy for aml
-
9:29
mds/aml overlap and novel therapies with dr. naval daver
-
1:22
dr. mannis talks about emerging treatments for acute myeloid leukemia
-
35:52
mid-year updates in aml research | dr. daver eha 2022 with q&a #aml
-
1:16
dr. mannis on targeted agents in the treatment of patients with aml
-
6:09
promising immunotherapy approaches in aml
-
1:18
dr. levis discusses the ideal use of quizartinib in flt3-itd aml
-
6:06
ash 2016 naval daver interview
-
33:39
virtual round table with md anderson part i - dr. naval daver - new & emerging therapies #aml
-
8:06
dr. desai discusses advances in treatment for patients with aml
-
1:40
the role of menin inhibitors in the treatment of aml
-
1:49
dr. daver on results of a combination study with azacitidine/nivolumab in aml
-
4:37
immunotherapy in acute myeloid leukemia